Edwards Announces Positive Data On Transfemoral Transcatheter Tricuspid Valve Replacement

(RTTNews) - Edwards Lifesciences Corp. (EW) said that one-year results on patients treated in TRISCEND study of the company's EVOQUE transcatheter tricuspid valve replacement system demonstrated favorable safety, efficacy and quality-of-life outcomes.

Patients enrolled in the TRISCEND study had symptomatic moderate or greater functional or degenerative tricuspid regurgitation (TR), despite optimal medical therapy.

The one-year outcomes demonstrated high survival of 90.1% and high freedom from heart failure hospitalization at 88.4%; significant and sustained TR reduction, with 97.6% of patients with mild or trace TR (n=84).

The data also demonstrated significantly improved functional and quality-of-life outcomes, with 93% of patients in NYHA Class I or II compared to 26% at baseline (n=89) and a 26-point increase in KCCQ score over baseline (n=102).

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.